Diabetes Case Reports

Abstract

The Effect of Oral Semaglutide on Urinary Albumin to Creatinine Ratio in Patients with Type 2 Diabetes

Masahiro Yano*, Sadahiko Uchimoto, Masami Nishimura and Saori Yamaguchi

Background: Oral semaglutide has been shown to have excellent effects such as reduction of HbA1c and weight loss. However, there are no reports of the effect of oral semaglutide on Urinary Albumin to Creatinine Ratio (UACR). In this study, we investigated the effect of oral semaglutide on UACR in patients with type 2 diabetes who switched from Dipeptidyl Peptidase-4 (DPP4) inhibitors to oral semaglutide.

Method: Thirty patients with type 2 diabetes (15 males, 15 females, average age 60.3 years old), whose UACR was measured before and after switching from DPP4 inhibitors to oral semaglutide, were investigated. It was compared between before and after 6.6 months on averages that body weight, systolic and diastolic blood pressure, HbA1c, Low-Density Lipoprotein Cholesterol (LDL-C), and UACR.

Result: After switching from DPP4 inhibitor to oral semaglutide, HbA1c decreased significantly (8.3 ± 1.1% before switching, 7.4 ± 0.9% after switching, p<0.001). Body weight (71.8 ± 13.7 kg before switching, 68.4 ± 12.6 kg after switching, p<0.001), systolic blood pressure (140.4 ± 17.0 mmHg before switching, 135.4 ± 13.8 mmHg after switching, p<0.01), LDL-C (111.1 ± 20.4 mg/dL before switching, 98.8 ± 21.5 mg/dL after switching mg/dL, p<0.01), and UACR (194.2 ± 311.8 mg/g・Cre before switching, 121.2 ± 224.3 mg/g・Cre after switching, p<0.001) were also significantly decreased.

Conclusion: Switching from DPP4 inhibitors to oral semaglutide resulted in reductions in HbA1c, body weight, systolic blood pressure, LDL-C, and UACR in patients with type 2 diabetes.

Published Date: 2023-08-02; Received Date: 2023-06-26